Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Emergent BioSolutions

The FDA concluded its inspection of Emergent BioSolutions Inc's (NYSE: EBS) troubled vaccine manufacturing plant in Baltimore after it stopped production on Monday. The agency released a couple of blistering observations on the cross-contamination, sanitary issues, and lack of staff training that caused ingredient mix-ups at the facility.

FDA's Inspection Of Emergent's COVID-19 Vaccine Baltimore Plant Outlines Concerns About Sanitary Conditions, Employee Training

The report said the facility did not properly train personnel or adequately clean the warehouse.

FDA Issues Scathing Report Of Baltimore Warehouse Where Johnson & Johnson Vaccines Were Ruined

J&J (JNJ) is set to resume shipments of its COVID-19 vaccine to European countries, following positive recommendation from EMA's Pharmacovigilance Risk Assessment Committee (PRAC).

J&J (JNJ) Gets Usage Guidance for COVID-19 Vaccine in Europe

Johnson & Johnson (JNJ) continued its long streak of earnings beat and outpaced revenue estimates. However, the company tightened its full-year guidance.

Healthcare ETFs in Focus Post JNJ's Q1 Earnings Results

The statement comes after the U.S. Food and Drug Administration flagged problems, including peeling paint and loose debris, during inspections at a U.S. plant in Baltimore that makes the drugmaker's COVID-19 vaccine and asked for remediation of the issues.

J&J says supply chain for COVID-19 vaccine to include 10 sites

Shares of Emergent BioSolutions Inc. were up 1.3% in trading on Wednesday after the Food and Drug Administration said it inspected a plant in Baltimore that had been scheduled to begin producing Johnson & Johnson's COVID-19 vaccine after reports emerged of cross-contamination in vaccine production there. J&J confirmed several weeks ago that quality standards had not been met at the Emergent facility.

FDA inspection of Emergent's COVID-19 vaccine plant identifies 'potential quality issues'

The Food and Drug Administration said Wednesday a Baltimore plant that ruined millions of Johnson & Johnson Covid-19 vaccine doses was unsanitary and unsuitable to manufacture the shots.

FDA finds poor conditions at Baltimore plant that ruined millions of doses of J&J Covid vaccine

The U.S. Food and Drug Administration (FDA) said it had completed its inspection of a U.S. plant that makes Johnson & Johnson's COVID-19 vaccine and asked for remediation of issues including peeling paint and loose debris at the site.

U.S. FDA finds peeling paint, debris at U.S. plant making J&J's COVID-19 vaccine

A Baltimore factory that botched the production of 15 million doses of the Johnson & Johnson COVID-19 vaccine has been cited for unsanitary conditions by the US Food and Drug Association. In a report on the factory for Emergent BioSolutions published by the FDA on Wednesday, officials said the facility had peeling paint and "brown residue" on the walls.

The FDA cited the vaccine plant that ruined millions of Johnson & Johnson doses for unsanitary conditions, finding "brown residue" on the walls and peeling paint

The European Medicines Agency demanded that a “warning about unusual blood clots with low blood platelets” be included in the product information of the Johnson & Johnson COVID-19 shots.

J&J resumes European COVID-19 vaccine rollout with regulator-mandated safety warning

Hello, Welcome to Insider Healthcare. I'm Lydia Ramsey Pflanzer, and today in healthcare news:

Europe's top regulator weighs in on J&J's COVID-19 vaccine

The healthcare giant also faces another challenge for its vaccine over the long term.

Will Blood Clot Issues Make Johnson & Johnson's COVID Vaccine a Loser?

Johnson & Johnson (NYSE: JNJ) said Tuesday that the European rollout of its COVID-19 vaccine is set to continue after it got the go-ahead from the regulator on the continent. What Happened: The multinational pharmaceutical giant said in a statement that the European Medical Agency's Pharmacovigilance Risk Assessment Committee had given updated guidance for the use of its COVID-19 vaccine.

Johnson & Johnson Set To Resume COVID-19 Vaccine Rollout In Europe — With A Warning On The Label

Kansas City Southern

Procter & Gamble

United Continental Hlds

United Airlines, Johnson & Johnson, Procter & Gamble, Kansas City Southern and IBM were our top stock trades for Wednesday. The post 5 Top Stock Trades for Wednesday: UAL, JNJ, PG, KSU, IBM appeared first on InvestorPlace.

5 Top Stock Trades for Wednesday: UAL, JNJ, PG, KSU, IBM

Shares of Johnson & Johnson (NYSE:JNJ) surged over 2% in morning trading on Tuesday on the back of the company reporting first-quarter revenue and earnings that topped consensus estimates.

Johnson & Johnson Rises on 1st-Quarter Earnings Beat

AstraZeneca

Biogen

Moderna

Pfizer

Sarepta Therapeutics

Vertex Pharmaceuticals

Investors may want to pay close attention to news coming down the pike soon that could affect the share prices of several pharma companies. The next two months are likely to see a wave of important updates about key products.

Key Decisions Coming on Products From Vertex, AstraZeneca and Other Pharmas

Johnson & Johnson topped first quarter expectations and hiked its quarterly dividend by a nickel, leading JNJ stock to inch higher Tuesday. Medical device and drug sales rose.

Bellwether J&J Squashes First-Quarter Views; Will Other Medical Stocks Follow?

Johnson & Johnson (JNJ) CEO Alex Gorsky on Q1 2021 Results - Earnings Call Transcript

Johnson & Johnson shares pushed to a three-week high Tuesday, with the company restarting shipments of its COVID-19 vaccine to Europe after the European Union's drug agency said its benefits outweigh the potential risk of a "rare" side effect of blood clots. The European Medicines Agency said Tuesday it found a possible link between the company's vaccine and "very rare" cases of "unusual blood clots with low blood platelets."

Johnson & Johnson jumps as vaccine shipments to Europe set to resume after regulator says benefits outweigh blood clot risks (JNJ, DJIA, INX)

Shipments of the coronavirus vaccine to Europe will resume.

Benefits of Johnson & Johnson vaccine outweigh 'very rare' blood clot risks, EU says

A CDC advisory committee is scheduled to meet Friday to discuss what's next for the J&J shot.

Johnson & Johnson vaccine ‘pause' isn't crimping confidence in the vaccination process, survey says

NIKE

Nike Inc (NYSE:NKE) shares are trading lower after Citigroup downgraded the stock from Buy to Neutral and lowered its price target from $160 to $140 per share. Nike is the largest athletic footwear and apparel brand in the world.

What's Going On With NKE Stock And JNJ Stock Today?

Shares of Johnson & Johnson jumped 2.6% toward a 12-week high in midday trading Tuesday, after the drug maker said it will resume shipments of its COVID-19 vaccine in Europe, after the European Medicines Agency said a warning about potential rare blood clots should be added. J&J said it will update its COVID-19 vaccine summary of product characteristics to include information on "the diagnosis and management of this very rare adverse event," after which shipment of the vaccine will resume to the European Union, Norway and Iceland.

J&J to resume COVID-19 vaccine shipments to EU, with a warning 'very rare' adverse events

The European Medicines Agency's (EMA) safety committee said that the Johnson & Johnson's (NYSE: JNJ) COVID-19 vaccine has possible links to rare blood clot incidents but reiterated, its benefits still outweighed the risk. The agency did recommend the shot with an added warning regarding the rare but sometimes fatal blood clots with low blood platelets occurring within three weeks of vaccination.

EMA Finds Potential Blood Clot Link With JNJ COVID-19 Shot, Adds Safety Warning

NEW BRUNSWICK, N.J., April 20, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) (the Company) today announced that the European Medicines Agency's (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) has provided updated guidance for use of the Company's COVID-19 vaccine and confirmed the overall benefit-risk profile remains positive.

News for Johnson & Johnson Stock (JNJ)